Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579446 · ClinicalTrials.gov registry record · Early Phase 1
Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 43
- Enrollment target
NCT03579446: Clinical Trial Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03579446 is a Early Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 43 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03579446, a Early Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This early phase I trial studies how well levorphanol works as a second line opioid in reducing pain in patients with cancer that may have spread to other places in the body. Levorphanol may work better in controlling cancer pain.
Primary Outcome
Bayesian methodology developed by Peter Thall will be used to monitor the study. This method decides whether levorphanol is promising relative to the standard medicine. Will estimate the proportion of successful opioid rotation along with a 95% confidence interval. Association between successful opioid rotation and demographic/clinical characteristics will be examined by Chi-squared test or Fisher's exact test when appropriate. Logistic regression model will be employed to assess the effect of d
Interventions
- DRUG Oxycodone
- DRUG Hydromorphone
- DRUG Morphine
- DRUG Hydrocodone
- DRUG Levorphanol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-11-29 |
| Est. Completion | 2023-06-15 |
| Phase | Early Phase 1 |
Why NCT03579446 stopped before completion
NCT03579446 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 5 interventions - of which Oxycodone is the first listed.
NCT03579446 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03579446 about?
NCT03579446 is a clinical study titled "Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer". This early phase I trial studies how well levorphanol works as a second line opioid in reducing pain in patients with cancer that may have spread to other places in the body. Levorphanol may work better in controlling cancer pain.
What is the current status of trial NCT03579446?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 43 participants. The study started on 2018-11-29. Estimated completion is 2023-06-15.
What interventions are being tested in trial NCT03579446?
The interventions under investigation include: Oxycodone (DRUG), Hydromorphone (DRUG), Morphine (DRUG), Hydrocodone (DRUG), Levorphanol (DRUG).
Who is sponsoring clinical trial NCT03579446?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03579446's enrollment target sits among peer trials
43 600th of 2000 higher than 1,396 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI